0001209191-23-045234.txt : 20230809
0001209191-23-045234.hdr.sgml : 20230809
20230809182138
ACCESSION NUMBER: 0001209191-23-045234
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230808
FILED AS OF DATE: 20230809
DATE AS OF CHANGE: 20230809
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hannah Brendan
CENTRAL INDEX KEY: 0001929422
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 231156601
MAIL ADDRESS:
STREET 1: 269 EAST GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Quince Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662774
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 901024039
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-910-5717
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Cortexyme, Inc.
DATE OF NAME CHANGE: 20160104
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-08
0
0001662774
Quince Therapeutics, Inc.
QNCX
0001929422
Hannah Brendan
C/O CORTEXYME, INC.
601 GATEWAY BLVD, #1250
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Business Officer
0
Common Stock
2023-08-08
4
P
0
71762
1.22
A
201555
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 to $1.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Brendan Hannah
2023-08-09